Toxicity hits BioNTech’s MediLink tie-up
A mysterious ASCO poster, patient deaths and now clinical hold; where next for BioNTech’s ADC deal?
We haven't lost focus, BioNTech insists
The company defends its cancer strategy, and says it's not a me-too developer.
ASCO 2024 – Enhertu nears its “ultralow” dream
But toxicity could hold back Destiny-Breast06's ability to change clinical practice.
ASCO 2024 – Blenrep “should return” to the US
Dreamm-8 is heralded as marking doctors’ ability to deal better with Blenrep’s toxicities.
ASCO 2024 – full Evoke-01 result adds to Gilead’s Trodelvy problems
Gilead came out swinging in second-line lung cancer, but it might have just whiffed.
ASCO 2024 preview – conjugates in focus
This weekend’s oncology conference will feature at least 30 different ADC projects.
